Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 1
Submit an article Journal homepage
488
Views
49
CrossRef citations to date
0
Altmetric
Review

Development of PARP inhibitors in oncology

Jordi Rodon UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, (Unit 455), 1515 Holcombe Blvd, Houston, TX 77030, USA [email protected]
,
Maria D Iniesta University of Michigan, Department of Internal Medicine and Comprehensive Cancer Center, Ann Arbor, MI, USA
&
Kyriakos Papadopoulos South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
Pages 31-43 | Published online: 21 Nov 2008

Bibliography

  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
  • Weinberg RA. The biology of cancer. New York: Garland Science, 2007
  • Bork P, Hofmann K, Bucher P, et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997;11(1):68-76
  • Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996;14(4):430-40
  • Simonin F, Menissier-de Murcia J, Poch O, et al. Expression and site-directed mutagenesis of the catalytic domain of human poly(ADP-ribose)polymerase in Escherichia coli. Lysine 893 is critical for activity. J Biol Chem 1990;265(31):19249-56
  • Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45(2):73-85
  • Trucco C, Oliver FJ, de Murcia G, Menissier-de Murcia J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res 1998;26(11):2644-9
  • de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997;94(14):7303-7
  • Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1(3):347-57
  • Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3(3):389-95
  • Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998;58(5):859-62
  • Wong AK, Pero R, Ormonde PA, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272(51):31941-4
  • Venkitaraman A. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108(2):171-82
  • Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913-7
  • Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21
  • Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13(9):2728-37
  • Cockcroft XL, Dillon KJ, Dixon L, et al. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2006;16(4)1040-4
  • Loh VM Jr, Cockcroft XL, Dillon KJ, et al. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2005;15(9):2235-8
  • Jagtap PG, Baloglu E, Southan GJ, et al. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 2005;48(16):5100-3
  • Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6(3):945-56
  • Kummar S, Kinders R, Gutierrez M, et al. Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):3518
  • Yang SX, Kummar S, Rubinstein L, et al. Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results [abstract 3580]. J Clin Oncol 2008;26(Suppl)
  • Yap TA, Boss DS, Fong PC, et al. First in human Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):3529
  • Fong PC, Boss DS, Carden CP, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a Phase I study [abstract 5510]. J Clin Oncol 2008;26(Suppl)
  • Plummer R, Middleton M, Wilson R, et al. First in human Phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. ASCO Annual Meeting Proceedings Part I. 2005;23(16S Suppl):3065
  • Kopetz S, Mita MM, Mok I, et al. First in human Phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors [abstract 3577]. J Clin Oncol 2008;26(Suppl)
  • Mahany JJ, Lewis N, Heath EI, et al. A Phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors [abstract 3579]. J Clin Oncol 2008;26(Suppl)
  • Available from: http://www.fda.org
  • Wang C, Bedikian A, Kim K, et al. Evaluation of Tolerability, Safety, and Pharmacokinetics of INO-1001 Plus Temozolomide (TMZ) in patients with Unresectable Stage III/IV Melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl):12015
  • Plummer P, Lorigan P, Evans J, et al. First and final report of a Phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl):8013
  • Sakai W, Swisher E M, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451(7182):1116-20
  • Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68(8):2581-6
  • Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451(7182):1111-5
  • Burger AM, Adams C, Horiba MN, et al The poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 potentiates the topoisomerase I poison irinotecan. AACR Annual Meeting; San Diego, CA. 2008
  • Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43(12):1791-801
  • Drew YC, Vong WT, Khan S, et al. Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? AACR Annual Meeting; San Diego, CA. 2008
  • McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66(16):8109-15
  • Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004;4(10):814-9
  • Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005;5(4):388-93
  • Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-74
  • Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418-23
  • Mason KA, Valdecanas D, Hunter NR, et al INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 2008;26(1):1-5
  • Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005;386(Pt 1):119-25
  • Weichselbaum RR, Little JB, Tomkinson K, et al. Repair of fractionated radiation in plateau phase cultures of human tumor cells and human multicellular tumor spheroids. Radiother Oncol 1984;2(1):41-7
  • Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol) 2004;16(1):29-39
  • Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13(10):3033-42
  • Burd R, Limesand K, Lavorgna L, et al. The selective PARP inhibitor, CEP-9722, exhibits significant radiosensitization against radioresistant U87 human glioblastoma xenografts and does not potentiate radiation-induced normal tissue toxicity. AACR Annual Meeting; San Diego, CA. 2008
  • Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96(1):56-67
  • Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007;13(3):832-8
  • Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8(7):2286-91
  • Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356(8):800-8
  • Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005;65(3):722-6
  • Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2(11):e1129
  • Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11(9):3402-9
  • Liu X, Palma J, Kinders R, et al. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem 2008
  • Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007;356(24):2538-40
  • Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18(3):522-8
  • Ferretti G, Felici A, Papaldo P, et al. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19(1):56-62
  • Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19(8):2334-56
  • Seiwert TY, Cohen EE, Wang X, et al. Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy [abstract 6003]. J Clin Oncol 2008;26(Suppl)
  • Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008;27(9):1368-77
  • Tong WM, Yang YG, Cao WH, et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 2007;26(26):3857-67
  • Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14(12):3916-25
  • Gutierrez M, Kummar S, Horneffer Y, et al. Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies. ASCO Annual Meeting Proceedings Part I. 2007;25(18S Suppl):14111
  • Mahany JJ, Lewis N, Rodon J, et al. A Phase 1B Study Evaluating BSI-201 in Combination with Chemotherapy in Subjects with Advanced Solid Tumors. ASCO annual meeting; Chicago, IL. 2008
  • Radovits T, Seres L, Gero D, et al. Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Exp Gerontol 2007;42(7):676-85
  • White AW, Curtin NJ, Eastman BW, et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 2004;14(10):2433-7
  • Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005;4(9):1364-8
  • Ossovskaya V, Alvares C, Kaldjian E, B. S. PARP1 gene over-expression in primary human cancers. A potential marker for PARP inhibition [abstract nr C125]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco, CA: AACR, Philadelphia, PA. 2007
  • Veuger SJ, Curtin NJ, Richardson CJ, et al. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63(18):6008-15
  • Brock WA, Milas L, Bergh S, et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004;205(2):155-60

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.